• Explore /
  • Poster
  • / Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.

Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.

Abstract Poster

Authors

null

Jennifer Rachel Eads

University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

Jennifer Rachel Eads , Paul J. Catalano , George A. Fisher Jr., Daniel Rubin , Andrei Iagaru , David S. Klimstra , Bhavana Konda , Myron S. Kwong , Jennifer A. Chan , Ana De Jesus-Acosta , Thorvardur Ragnar Halfdanarson , Walid Labib Shaib , Heloisa P. Soares , Sung Chul Hong , Terence Z. Wong , Peter J. O'Dwyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT02595424

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4020)

DOI

10.1200/JCO.2022.40.16_suppl.4020

Abstract #

4020

Poster Bd #

8

Abstract Disclosures

Similar Posters

First Author: Jennifer Rachel Eads

First Author: Robert Lance Fine

First Author: Dawei Chen

First Author: Armelle Vinceneux